AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17712755 — intervention group
Group type: COMPARATOR
Intervention: Isoniazid plus rifampin for 4 months (group C)
Number of subjects: 926
Study 17712755 — intervention group
Group type: COMPARATOR
Intervention: Isoniazid plus rifampin for 3 months (group D)
Number of subjects: 926
Study 17712755 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 926
Study 16371678 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (usual medication)
Number of subjects: 12
Study 16371678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 12226149 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 326
Study 12226149 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 326
Study 12226149 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 326
Study 10447989 — intervention group
Group type: EXPERIMENTAL
Intervention: Right hemisphere-damaged (RHD) speakers
Number of subjects: 0
Study 10447989 — intervention group
Group type: COMPARATOR
Intervention: Nonneurological control subjects
Number of subjects: 0
Study 8524681 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic monitoring (capnograph and pulse oximeter)
Number of subjects: 39
Study 8524681 — intervention group
Group type: COMPARATOR
Intervention: Traditional monitoring (visual assessment and auscultation)
Number of subjects: 39
Study 8524681 — intervention group
Group type: EXPERIMENTAL
Intervention: Capnography (part of electronic monitoring)
Number of subjects: 39
Study 8524681 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse oximetry (part of electronic monitoring)
Number of subjects: 39
Study 2193318 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiation (31.5 Gy in 3.5 weeks)
Number of subjects: 138
Study 2193318 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiation
Number of subjects: 138
Study 2193318 — intervention group
Group type: COMPARATOR
Intervention: Control (immediate surgery)
Number of subjects: 138
Study 389259 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilisation on the fifth day after myocardial infarction
Number of subjects: 742
Study 389259 — intervention group
Group type: COMPARATOR
Intervention: Mobilisation on the tenth day after myocardial infarction
Number of subjects: 742
Study 31919768 — intervention group
Group type: EXPERIMENTAL
Intervention: Postgraduate freshmen evaluating nodules using ACR TI-RADS
Number of subjects: 400
Study 31919768 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-evaluation of Group 4 by postgraduate freshmen
Number of subjects: 400
Study 31769998 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug repurposing candidates identified through integration of pharmacodynamic and marketing variables from DrugBank and genomic data from BioVU.
Number of subjects: 0
Study 31769998 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 repurposing candidates across 7 disease areas.
Number of subjects: 0
Study 28676927 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthesia (LA)
Number of subjects: 119
Study 28676927 — intervention group
Group type: COMPARATOR
Intervention: Spinal anaesthesia (SA)
Number of subjects: 119
Study 25363555 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line therapy (PPI-based triple therapy for seven days)
Number of subjects: 2202
Study 25363555 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line therapy (moxifloxacin-based triple therapy or bismuth-based quadruple therapy)
Number of subjects: 2202
Study 25363555 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-line therapy (unused MA or QUAD)
Number of subjects: 2202
Study 25363555 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with resistance to clarithromycin
Number of subjects: 2202
Study 25363555 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment adherence
Number of subjects: 2202
Study 24055124 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak upright bicycle digital echocardiography (UBE)
Number of subjects: 86
Study 24055124 — intervention group
Group type: COMPARATOR
Intervention: Post-treadmill digital echocardiography (post-TME)
Number of subjects: 86
Study 21346202 — intervention group
Group type: EXPERIMENTAL
Intervention: Static wrist extensions against gravity
Number of subjects: 68
Study 21346202 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow wrist extension and flexion movements
Number of subjects: 68
Study 21346202 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement conditions
Number of subjects: 68
Study 19738139 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical antiarrhythmic drug (AAD) therapy for 6 weeks after AF ablation
Number of subjects: 110
Study 19738139 — intervention group
Group type: COMPARATOR
Intervention: No antiarrhythmic therapy (no-AAD group)
Number of subjects: 110
Study 19738139 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical antiarrhythmic drug (AAD) therapy
Number of subjects: 110
Study 17557041 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose proton pump inhibitor (PPI) therapy
Number of subjects: 0
Study 17557041 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic antireflux surgery
Number of subjects: 0
Study 17557041 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 0
Study 17557041 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life measures
Number of subjects: 0
Study 15049979 — intervention group
Group type: EXPERIMENTAL
Intervention: (‐7,5)proPSA
Number of subjects: 431
Study 15049979 — intervention group
Group type: EXPERIMENTAL
Intervention: hK2
Number of subjects: 431
Study 15049979 — intervention group
Group type: EXPERIMENTAL
Intervention: fPSA
Number of subjects: 431
Study 15049979 — intervention group
Group type: EXPERIMENTAL
Intervention: (‐7,5)proPSA and hK2 combined
Number of subjects: 431
Study 15049979 — intervention group
Group type: EXPERIMENTAL
Intervention: (‐7,5)proPSA, hK2, and fPSA
Number of subjects: 431
Study 11506059 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated enriched sunflower oil diet (40% to 42% of energy from fat, 26% to 28% from monounsaturated fat, 40% to 45% from carbohydrate)
Number of subjects: 28
Study 11506059 — intervention group
Group type: COMPARATOR
Intervention: Low fat, high carbohydrate diet (22% to 25% of energy from total fat, 7% to 8% of energy from monounsaturated fat, 55% to 60% of energy from carbohydrate)
Number of subjects: 28
Study 9772944 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 19435
Study 7917776 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal morphine (10 mg)
Number of subjects: 12
Study 7917776 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine (10 mg over 20 min)
Number of subjects: 12
Study 3045441 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium (Li) therapy
Number of subjects: 53
Study 3045441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 29131513 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular ultrasound scanning (VUS)
Number of subjects: 300
Study 29131513 — intervention group
Group type: COMPARATOR
Intervention: Control (operator's discretion)
Number of subjects: 300
Study 26797697 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP (Platelet-Rich Plasma)
Number of subjects: 111
Study 26797697 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP+HA (Platelet-Rich Plasma + Hyaluronic Acid)
Number of subjects: 111
Study 26797697 — intervention group
Group type: COMPARATOR
Intervention: HA (Hyaluronic Acid)
Number of subjects: 111
Study 26797697 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP
Number of subjects: 111
Study 26797697 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP+HA
Number of subjects: 111
Study 25712473 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin‐to‐skin rewarming
Number of subjects: 200
Study 25712473 — intervention group
Group type: COMPARATOR
Intervention: Radiant rewarming
Number of subjects: 200
Study 23085153 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5mg daily for six months
Number of subjects: 42
Study 23085153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 20807463 — intervention group
Group type: EXPERIMENTAL
Intervention: New energy requirement model for controlling energetic intake
Number of subjects: 434
Study 18676693 — intervention group
Group type: EXPERIMENTAL
Intervention: Aplaviroc (GW873140)
Number of subjects: 0
Study 16669728 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (15 or 30 mg/day)
Number of subjects: 161
Study 16669728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 12784273 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 U of botulinum toxin type A (Dysport) injected into the parotids and submandibular glands
Number of subjects: 20
Study 12784273 — intervention group
Group type: COMPARATOR
Intervention: 2 ml of placebo injected into the parotids and submandibular glands
Number of subjects: 20
Study 11171715 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg/d for 3 days)
Number of subjects: 12
Study 11171715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11171715 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 12
Study 9169997 — intervention group
Group type: EXPERIMENTAL
Intervention: High-performance liquid chromatography (HPLC)
Number of subjects: 41
Study 9169997 — intervention group
Group type: COMPARATOR
Intervention: Non-HPLC measurement
Number of subjects: 41
Study 9169997 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenergic blockade
Number of subjects: 41
Study 9169997 — intervention group
Group type: EXPERIMENTAL
Intervention: HPLC measurement
Number of subjects: 41
Study 1554077 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented anterior cruciate ligament repair with the iliotibial band
Number of subjects: 107
Study 1554077 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment of the anterior cruciate ligament
Number of subjects: 107
Study 4019257 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg ascorbic acid twice a day for 60 days
Number of subjects: 54
Study 4019257 — intervention group
Group type: COMPARATOR
Intervention: Sugar placebos
Number of subjects: 54
Study 31026185 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health promotion program (12 weeks)
Number of subjects: 86
Study 31026185 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (WCG)
Number of subjects: 86
Study 28389610 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial treatment
Number of subjects: 487
Study 28389610 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 487
Study 26205023 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU/day edible vitamin D for 15 weeks
Number of subjects: 208
Study 26205023 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 208
Study 26205023 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 208
Study 23697585 — intervention group
Group type: EXPERIMENTAL
Intervention: LCn‐3PUFA (fish oil) 6 × 1 g capsules/d
Number of subjects: 35
Study 23697585 — intervention group
Group type: COMPARATOR
Intervention: Placebo (monounsaturated oil) 6 × 1 g capsules/d
Number of subjects: 35
Study 21550907 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMUS Element platinum chromium everolimus‐eluting stent (EES)
Number of subjects: 100
Study 19489494 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrounded needling therapy
Number of subjects: 60
Study 19489494 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (Indomethacin and Allopurinol)
Number of subjects: 60
Study 17272406 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment (8-10 days)
Number of subjects: 11
Study 17272406 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (8-10 days)
Number of subjects: 11
Study 17272406 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic hypoxia (after treatment with testosterone or placebo)
Number of subjects: 11
Study 12527970 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnitopuncture applied to Dazhui (DU14) and Neiguan (PC6) points
Number of subjects: 40
Study 12527970 — intervention group
Group type: COMPARATOR
Intervention: Non-acupuncture points (1.5 cm away from DU14 and PC6)
Number of subjects: 40
Study 10561314 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT) measurements of thoracic ratio (TR)
Number of subjects: 95
Study 10561314 — intervention group
Group type: EXPERIMENTAL
Intervention: Longest diameter of the largest individual nodal mass (LIM(CT)) greater than 10 cm
Number of subjects: 95
Study 10561314 — intervention group
Group type: COMPARATOR
Intervention: Chest Radiography (CXR) measurements of thoracic ratio (TR)
Number of subjects: 95
Study 10180870 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise programme
Number of subjects: 97
Study 10180870 — intervention group
Group type: COMPARATOR
Intervention: Indifferent patients
Number of subjects: 97
Study 10180870 — intervention group
Group type: COMPARATOR
Intervention: Conventional GP management
Number of subjects: 97
Study 1679645 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg flumazenil
Number of subjects: 18
Study 1679645 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of flumazenil (2-5 mg)
Number of subjects: 18
Study 1679645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 7041850 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback
Number of subjects: 22
Study 7041850 — intervention group
Group type: COMPARATOR
Intervention: Simple exercise therapy
Number of subjects: 22
Study 6691783 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 87
Study 6691783 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 87
Study 6691783 — intervention group
Group type: EXPERIMENTAL
Intervention: CT plus pharmacotherapy
Number of subjects: 87
Study 6691783 — intervention group
Group type: COMPARATOR
Intervention: CT plus active placebo
Number of subjects: 87
Study 31664593 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental services received by children up to 6 years old in eastern regions of Austria
Number of subjects: 130895
Study 31664593 — intervention group
Group type: EXPERIMENTAL
Intervention: Children needing more than four dental services
Number of subjects: 130895
Study 31664593 — intervention group
Group type: COMPARATOR
Intervention: Smaller random sample of 3000 children
Number of subjects: 130895
Study 28333879 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained Group (monthly IAI for 3 months, then every 2 months for 12 months)
Number of subjects: 39
Study 28333879 — intervention group
Group type: EXPERIMENTAL
Intervention: PRN Group (1 IAI at randomization, then monthly PRN IAI for 12 months)
Number of subjects: 39
Study 27995141 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D laparoscopic platform
Number of subjects: 10
Study 27995141 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D laparoscopic platform
Number of subjects: 10
Study 27995141 — intervention group
Group type: COMPARATOR
Intervention: 2D and 3D laparoscopic platforms
Number of subjects: 10
Study 24161334 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) for technically inoperable patients (TI)
Number of subjects: 369
Study 24161334 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) for clinically inoperable patients (CLI)
Number of subjects: 369
Study 24161334 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy for both TI and CLI patients
Number of subjects: 369
Study 22403196 — intervention group
Group type: EXPERIMENTAL
Intervention: Wellness Portal
Number of subjects: 538
Study 22403196 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 538
Study 20487567 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuragen PN
Number of subjects: 60
Study 20487567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 18545057 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (10 mg/day, intravenous)
Number of subjects: 36
Study 18545057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 15918128 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior capsulolaboral reconstruction according to Jobe
Number of subjects: 24
Study 12840614 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatment procedures including epidural steroids, trigger point injections, and cognitive-behaviorally oriented psychoeducational groups
Number of subjects: 74
Study 11142163 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU/Leucovorin (LV)
Number of subjects: 0
Study 11142163 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intraportal 5-FU infusion
Number of subjects: 0
Study 11142163 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU and levamisol (LEV)
Number of subjects: 0
Study 11142163 — intervention group
Group type: COMPARATOR
Intervention: UFT/LV (oral chemotherapy)
Number of subjects: 0
Study 11142163 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (CPT-11)
Number of subjects: 0
Study 11142163 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study 11142163 — intervention group
Group type: COMPARATOR
Intervention: UFT alone
Number of subjects: 0
Study 8864039 — intervention group
Group type: EXPERIMENTAL
Intervention: Females (with a tendency to turn towards the right)
Number of subjects: 0
Study 8864039 — intervention group
Group type: EXPERIMENTAL
Intervention: Males (with a tendency to turn towards the right)
Number of subjects: 0
Study 8864039 — intervention group
Group type: EXPERIMENTAL
Intervention: Females using oral contraceptives
Number of subjects: 0
Study 8864039 — intervention group
Group type: COMPARATOR
Intervention: Regularly cycling females
Number of subjects: 0
Study 1522191 — intervention group
Group type: EXPERIMENTAL
Intervention: GIFT
Number of subjects: 151
Study 1522191 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF
Number of subjects: 151
Study 1522191 — intervention group
Group type: EXPERIMENTAL
Intervention: IUI/superovulation
Number of subjects: 151
Study 6361628 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone, 500 mg two nocte
Number of subjects: 24
Study 6361628 — intervention group
Group type: COMPARATOR
Intervention: Naproxen, 250 mg two nocte and one mane
Number of subjects: 24
Study 31609677 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper gastrointestinal (UGI) series
Number of subjects: 162
Study 31609677 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower gastrointestinal (LGI) series
Number of subjects: 162
Study 31609677 — intervention group
Group type: EXPERIMENTAL
Intervention: Voiding cystourethrogram (VCUG)
Number of subjects: 162
Study 31609677 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified barium swallow (MBS)
Number of subjects: 162
Study 29994994 — intervention group
Group type: EXPERIMENTAL
Intervention: Adelta fiber activation
Number of subjects: 0
Study 29994994 — intervention group
Group type: COMPARATOR
Intervention: C fiber activation
Number of subjects: 0
Study 27596132 — intervention group
Group type: EXPERIMENTAL
Intervention: Icosapent ethyl 4 g/day
Number of subjects: 470
Study 27596132 — intervention group
Group type: EXPERIMENTAL
Intervention: Icosapent ethyl 2 g/day
Number of subjects: 470
Study 27596132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 470
Study 24067785 — intervention group
Group type: EXPERIMENTAL
Intervention: hyperimmune caprine serum (AIMSPRO)
Number of subjects: 20
Study 24067785 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 22070919 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency rTMS preceded by 5 minutes of 6 Hertz rTMS (priming rTMS)
Number of subjects: 23
Study 22070919 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency rTMS without priming
Number of subjects: 23
Study 20512064 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest press exercise at 44 degrees
Number of subjects: 15
Study 20512064 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest press exercise at 56 degrees
Number of subjects: 15
Study 20512064 — intervention group
Group type: COMPARATOR
Intervention: Chest press exercise at 0 degrees
Number of subjects: 15
Study 20512064 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest press exercise at 28 degrees
Number of subjects: 15
Study 17928580 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ceftriaxone
Number of subjects: 37
Study 17928580 — intervention group
Group type: COMPARATOR
Intervention: IV placebo
Number of subjects: 37
Study 15950657 — intervention group
Group type: EXPERIMENTAL
Intervention: Excision
Number of subjects: 2
Study 15950657 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation
Number of subjects: 2
Study 15950657 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 2
Study 11830339 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon treatment
Number of subjects: 164
Study 11830339 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 164
Study 10513357 — intervention group
Group type: EXPERIMENTAL
Intervention: Posteromedial release
Number of subjects: 20
Study 10513357 — intervention group
Group type: COMPARATOR
Intervention: Complete circumferential subtalar release
Number of subjects: 20
Study 7560220 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered 0.3% acetylsalicylic acid (ASA)
Number of subjects: 60
Study 7560220 — intervention group
Group type: EXPERIMENTAL
Intervention: Water (500 ml)
Number of subjects: 60
Study 7560220 — intervention group
Group type: COMPARATOR
Intervention: Normal oral hygiene alone
Number of subjects: 60
Study 1834396 — intervention group
Group type: EXPERIMENTAL
Intervention: Picotamide (300 mg b.i.d.)
Number of subjects: 87
Study 1834396 — intervention group
Group type: COMPARATOR
Intervention: Low-dosage aspirin (300 mg/die)
Number of subjects: 87
Study 7127989 — intervention group
Group type: EXPERIMENTAL
Intervention: Syringe for medication delivery
Number of subjects: 72
Study 7127989 — intervention group
Group type: COMPARATOR
Intervention: Teaspoon for medication delivery
Number of subjects: 72
Study 31577372 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain English abstracts
Number of subjects: 41